BFM
BIOC

Boothbay Fund Management’s Biocept, Inc. BIOC Stock Holding History

Boothbay Fund Management’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,529
Closed -$28.5K – 2277
2023
Q2 		$28.5K Buy
+23,529
New +$133K ﹤0.01% 1704

Other funds holding BIOC

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Boothbay Fund Management's BIOC Position: Q3 2023 in Review

Boothbay Fund Management sold out of Biocept, Inc. (BIOC) in Q3 2023, closing a stake of 23,529 shares — an estimated $28.5K sold.

Boothbay Fund Management first reported a position in BIOC in Q2 2023 and held it in 1 quarter. The position peaked at $28.5K in Q2 2023. 13 funds tracked by Wall St. Rank hold BIOC as of Q3 2023.

  • Boothbay Fund Management reported no remaining Biocept, Inc. position as of Q3 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 23,529 Biocept, Inc. shares in Q3 2023, an estimated $28.5K.
  • Boothbay Fund Management first reported a position in Biocept, Inc. in Q2 2023 and held it in 1 quarter.
  • Boothbay Fund Management's Biocept, Inc. position peaked at $28.5K in Q2 2023.
  • 13 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.